PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19583730-0	2010	Dicoumarol enhances doxorubicin-induced cytotoxicity in p53 wild-type urothelial cancer cells through p38 activation.	Dicumarol	0-10	mitogen-activated protein kinase 14	Homo sapiens	102-105	
19583730-8	2010	The combined treatment with dicoumarol suppressed p53/p21 induction by doxorubicin and resulted in sequential p38 MAPK activation, myeloid cell leukaemia 1 suppression and caspase cleavage.	Dicumarol	28-38	mitogen-activated protein kinase 14	Homo sapiens	110-113	
19583730-9	2010	The synergistic effect of doxorubicin/dicoumarol was suppressed by the p38 MAPK inhibitor SB202190 and, furthermore, p21 knockdown with shRNA transfection made RT112 cells six times more susceptible to doxorubicin with p38 MAPK activation.	Dicumarol	38-48	mitogen-activated protein kinase 14	Homo sapiens	71-74	
19583730-9	2010	The synergistic effect of doxorubicin/dicoumarol was suppressed by the p38 MAPK inhibitor SB202190 and, furthermore, p21 knockdown with shRNA transfection made RT112 cells six times more susceptible to doxorubicin with p38 MAPK activation.	Dicumarol	38-48	mitogen-activated protein kinase 14	Homo sapiens	219-222	
19583730-10	2010	CONCLUSION: These results suggest that concomitant use of dicoumarol could enhance the cytotoxicity of doxorubicin in urothelial cancer cells with wt-p53 through the p53/p21/p38 MAPK pathways.	Dicumarol	58-68	mitogen-activated protein kinase 14	Homo sapiens	174-177